2025年
1.Sakai K, Hamamura A, Yoshimura Y, Abe M, Ogawa Y, Tanaka K, Hattori N, Tokugawa T, Kanai R, Ikejiri F, Takeyama M, Taoka T, Fujita N, Kanaya M, Koh K, Shiragami H, Azumi H, Saito K, Matsumoto M.
Therapeutic switch from plasma to recombinant ADAMTS13 in patients with congenital TTP from Japanese real-world-data.
Blood. 2025 Mar 16: blood.2024027516. doi: 10.1182/blood.2024027516.
2.Tanaka H, Sakai K, Tamura S, Shiwaku H, Nakamura J, Ueda Y, Bamba S, Nishikubo M, Nagai Y, Matsumoto M.
Challenges in managing iTTP: Insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.
Ann Hematol. 2025 Mar 19. doi: 10.1007/s00277-025-06318-w.
2024年
1.Saito K, Sakai K, Kubo M, Azumi H, Hamamura A, Ochi S, Amagase H, Kunieda H, Ogawa Y, Yagi H, Matsumoto M.
Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese patients with iTTP.
Blood Adv. 2023012451. doi. 10.1182/bloodadvances.2023012451.
2.Sakatoku K, Murata M, Shimazu Y, Uchida N, Yoshihara S, Uehara Y, Takahashi S, Kobayashi H, Tanaka H, Nakano N, Ishimura F, Ichinohe T, Atsuta Y,Nagamura-Inoue T, Nakamae H.
Comparison of haploidentical transplantation and single cord blood transplantation for myelofibrosis.
Bone Marrow Transplant. 59(5) 705-707,2024. doi: 10.1038/s41409-024-02244-z.
3.Asada S, Namisaki T, Keji K, Takuya H, Kubo T, Akahane T, Kawaratani H, Nishimura N, Takeda S, Masuda H, Shibamoto A, Inoue T, Iwai S, Tomooka F, Tsuji Y, Fujinaga Y, Kitagawa K, Mitoro A, Sato S, Matsumoto M, Yoshiji H.
VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
Digestive Diseases and Sciences. 69(3) 851-869,2024. doi: 10.1007/s10620-023-08257-w.
4.Suzuki J, Namisaki T, Takya H, Kaji K, Nishimura N. Shibamoto A, Asada S, Kubo T, Iwai S, Tomooka F, Takeda S, Koizumi A, Tanaka M, Matsuda T, Inoue T, Fujimoto Y, Tsuji Y, Fujinaga Y, Sato S, Kitagawa K, Kawaratani H, Akahane T, Mitoro A, Matsumoto M, Asada K, Yoshiji H.
ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis.
International Journal of Molecular Sciences. 25(5)2678-2678, 2024. doi:10.3390/ijms25052678.
5.Iwai S, Akahane T, Takaya H, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Nishimura N, Kitagawa K, Kaji K, Kawaratani H, Namisaki T, Matsumoto M, Yoshiji H.
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus-related liver cirrhosis.
Hepatology research : the official journal of the Japan Society of Hepatology. 54(12)1116-1127, 2024. doi:10.1111/hepr.14077.
6.Yamada S, Sakai K, Kubo M, Okumura H, Asakura H, Miyamoto T, Matsumoto M.
Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy.
Research and Practice in Thrombosis and Haemostasis. 8(5):102517-102517, 2024. doi:10.1016/j.rpth.2024.102517.
7.Imada K, Miyakawa Y, Ichikawa S, Uchiyama H, Ueda Y, Hashimoto Y, Nishimi M, Tsukamoto M, Tahara S, Matsumoto M.
Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan.
Thrombosis Journal. 22(1)72-72, 2024. doi: 10.1186/s12959-024-00642-3.
8.Uchihara M, Sakai K, Shibata K, Saito K, Lammle B, Matsumoto M.
Immune-mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia : A case report.
British Journal of Haematology. 205(4)1649-1652, 2024. doi: 10.1111/bjh.19717.
9.Kubo M, Konko K, Kinoshita E, Uemae S, Kobayashi K, Hayashi Y, Kan A, Fujimura Y, Matsumoto M.
A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies.
J Thromb Haemost. 23(3)957-967, 2024. doi: 10.1016/j.jtha.2024.11.020.
10.Matsumoto M, Shimono A, Yokosawa J, Hirose K, Wang E, Maruyama S.
Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial.
Thrombosis Journal. 22(1)93-93, 2024. doi: 10.1186/s12959-024-00652-1.
2023年
1. Azumi H, Kubo M, Otani A, Ochi S, Kobayashi S, Miyataka Y, Nakamura F, Yagi H.
Patient with Adult T-cell Leukemia and Lung Infection caused by Mycobacterium abscessus: Successful Treatment with Intensive Chemotherapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report.
Intern Med. 2023 Dec 11. doi. 10.2169/internalmedicine.1181-22. Online ahead of print.
2.Sakai K, Matsumoto M.
Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura. Journal of clinical medicine. 12(10) 2023. doi.10.3390/jcm12103365.
3. Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, Yagi H, Ogawa Y, Sakai K, Miyata T, Morishita E, Fujimura Y; For TTP group of Blood Coagulation Abnormalities Research Study Team, Research on Rare and Intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan.
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
Int J Hematol. 118(5):529-546, 2023. doi.10.1007/s12185-023-03657-0.
4. Fujioka N, Kai Y, Kataoka R, Suzuki K, Sakaguchi K, Yamamoto Y, Kawaguchi T, Sawabata N, Tanaka H, Matsuoka M, Takeda M, Muro S.
Primary pulmonary diffuse large B-cell lymphoma presenting multiple nodules mimicking metastasis: A case report. Respirol Case Rep.2023 Feb 22;11(3):e01111.doi. 10.1002/rcr2.1111.
